StockData
Anavex Life Sciences Corp. logo

Anavex Life Sciences Corp. (AVXL) stock

AVXLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 28, 2026Score 6/30
$0.74−0.08 (-9.49%)

Close on Nov 17, 2026Market cap $68.60MP/E –Yield –

Anavex Life Sciences enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Anavex Life Sciences's enterprise value was -$20.07M on Nov 11, 2026, against $229.36M a year earlier. Over the last 5 years it ranged from -$20.07M to $1.16B, with a median of $508.48M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026-$20.07M-109.7%
2025Dec 31, 2025$205.96M-73.5%
2024Dec 31, 2024$778.52M+27.0%
2023Dec 29, 2023$613.02M+7.1%
2022Dec 30, 2022$572.59M-50.8%
2021Dec 31, 2021$1.16B+280.8%
2020Dec 31, 2020$305.80M+167.8%
2019Dec 31, 2019$114.18M+134.3%
2018Dec 31, 2018$48.73M-56.5%
2017Dec 29, 2017$112.08M-16.4%
2016Dec 30, 2016$134.04M-17.9%
2015Dec 31, 2015$163.20M+2097.7%
2014Dec 31, 2014$7.43M-17.2%
2013Dec 31, 2013$8.96M-62.5%
2012Dec 31, 2012$23.88M-26.0%
2011Dec 30, 2011$32.28M-62.3%
2010Dec 31, 2010$85.57M–

More Anavex Life Sciences figures

See a number that looks wrong?